A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 166 participants.
Also called NCT01477853
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 166 participants
- Sponsor
- Registry
-
NCT01477853 -
2011-003600-20
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01477853. Randomized; double masking; primary purpose treatment. Start 2011-10-24 (actual); primary completion 2012-12-04 (actual). Results posted on 2016-10-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Atorvastatin
- Intervention (Other)
- Placebo to sitagliptin
- Intervention (Other)
- Placebo to atorvastatin
- Intervention (Drug)
- Metformin (open-label)
- Intervention (Drug)
- Glimepiride (open-label)
- Intervention (Drug)
- Glimepiride (double-blind)
- Intervention (Drug)
- Placebo to glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01477853- Content hash
c051278cca7f50b2686c383cfdb03500bcc0515348c8b53bd1052d0d3383420c